Inclusion complex of ITH12674 with 2-hydroxypropyl-β-cyclodextrin: Preparation, physical characterization and pharmacological effect

Carbohydrate Polymers

Volumn 157, Issue , 2017, Pages 94-104

  Michalska, Patrycja ^a,b   Wojnicz, Aneta ^a,b   Ruiz Nuño, Ana ^a,b   Abril, Sheila ^a,b   Buendia, Izaskun ^a   León, Rafael ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

2 Hydroxypropyl cyclodextrin; Inclusion complex; ITH12674; Nrf2 inducer; Stability

Indexed keywords

CONVERGENCE OF NUMERICAL METHODS; SOLUBILITY;

ANTI-INFLAMMATORY RESPONSE; INCLUSION COMPLEX; ITH12674; NRF2 INDUCER; PHARMACOLOGICAL EFFECTS; PHYSICAL CHARACTERIZATION; PHYSICOCHEMICAL PROPERTY; PRECLINICAL DEVELOPMENT;

ANTIOXIDANTS;

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; ISOTHIOCYANIC ACID DERIVATIVE; ITH12674; MELATONIN;

ANALOGS AND DERIVATIVES; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; INFRARED SPECTROSCOPY; SOLUBILITY;

2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; ISOTHIOCYANATES; MELATONIN; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84988890305     PISSN: 01448617     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carbpol.2016.09.072     Document Type: Article

References (29)

1. Bernini, A., Spiga, O., Ciutti, A., Scarselli, M., Bottoni, G., Mascagni, P.,. Niccolai, N., NMR studies of the inclusion complex between beta-cyclodextrin and paroxetine. European Journal of Pharmaceutical Sciences 22:5 (2004), 445–450.
2. Brewster, M.E., Loftsson, T., Cyclodextrins as pharmaceutical solubilizers. Advanced Drug Delivery Reviews 59:7 (2007), 645–666.
3. Buendia, I., Michalska, P., Navarro, E., Gameiro, I., Egea, J., Leon, R., Nrf2-ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases. Pharmacology & Therapeutics 157 (2016), 84–104.
4. Chamorro, A., Dirnagl, U., Urra, X., Planas, A.M., Neuroprotection in acute stroke: Targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurology 15:8 (2016), 869–881.
5. Dandawate, P., Vemuri, K., Khan, E.M., Sritharan, M., Padhye, S., Synthesis: Characterization and anti-tubercular activity of ferrocenyl hydrazones and their beta-cyclodextrin conjugates. Carbohydrate Polymers 108 (2014), 135–144.
6. EMA, C. f. H. M. Products, (eds.) Background review for cyclodextrins used as excipients, Vol. EMA/CHMP/333892/2013, 2014, EMA: European Medicines Agency.
7. Egea, J., Buendia, I., Parada, E., Navarro, E., Leon, R., Lopez, M.G., Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection. Biochemical Pharmacology 97:4 (2015), 463–472.
8. Egea, J., Buendia, I., Parada, E., Navarro, E., Rada, P., Cuadrado, A.,. Leon, R., Melatonin-sulforaphane hybrid ITH12674 induces neuroprotection in oxidative stress conditions by a ‘drug-prodrug' mechanism of action. British Journal of Pharmacology 172:7 (2015), 1807–1821.
9. Gerber, P.R., Muller, K., MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry. Journal of Computer-Aided Molecular Design 9:3 (1995), 251–268.
10. Ghosh, I., Bose, S., Vippagunta, R., Harmon, F., Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. International Journal of Pharmaceutics 409:1–2 (2011), 260–268.
11. Gould, S., Scott, R.C., 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food and Chemical Toxicology 43:10 (2005), 1451–1459.
12. Higuchi, T., Connors, K.A., Phase solubility techniques. Advances in Analytical Chemistry and Instrumentation 4 (1965), 117–212.
13. Jaffer, H., Morris, V.B., Stewart, D., Labhasetwar, V., Advances in stroke therapy. Drug Delivery and Translational Research 1:6 (2011), 409–419.
14. Jun, S.W., Kim, M.S., Kim, J.S., Park, H.J., Lee, S., Woo, J.S.,. Hwang, S.J., Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. European Journal of Pharmaceutics and Biopharmaceutics 66:3 (2007), 413–421.
15. Kristian, T., Siesjo, B.K., Calcium in ischemic cell death. Stroke 29:3 (1998), 705–718.
16. Liao, Y., Zhang, X., Li, C., Huang, Y., Lei, M., Yan, M.,. Zhao, C., Inclusion complexes of HP-beta-cyclodextrin with agomelatine: Preparation, characterization: Mechanism study and in vivo evaluation. Carbohydrate Polymers 147 (2016), 415–425.
17. Marques, H.C., Hadgraft, J., Kllaway, I., Studies of cyclodextrin inclusion complexes I: The salbutamol-cyclodextrin complex as studies by phase solubility and DSC. International Journal of Pharmaceutics 63 (1990), 259–266.
18. Marsac, P.J., Li, T., Taylor, L.S., Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharmaceutical Research 26:1 (2009), 139–151.
19. Patel, V.F., Sarai, J., Synergistic effect of hydrotrope and surfactant on solubility and dissolution of atorvastatin calcium: Screening factorial design followed by ratio optimization. Indian Journal of Pharmaceutical Sciences 76:6 (2014), 483–494.
20. Pralhad, T., Rajendrakumar, K., Study of freeze-dried quercetin-cyclodextrin binary systems by DSC, FT-IR, X-ray diffraction and SEM analysis. Journal of Pharmaceutical and Biomedical Analysis 34:2 (2004), 333–339.
21. Qiu, N., Cheng, X., Wang, G., Wang, W., Wen, J., Zhang, Y.,. Chen, L., Inclusion complex of barbigerone with hydroxypropyl-beta-cyclodextrin: Preparation and in vitro evaluation. Carbohydrate Polymers 101 (2014), 623–630.
22. Song, L.X., Bai, L., Xu, X.M., He, J., Pan, S.Z., Inclusion complexation, encapsulation interaction and inclusion number in cyclodextrin chemistry. Coordination Chemistry Reviews 253:9–10 (2009), 1276–1284.
23. Tao, T., Zhao, Y., Wu, J., Zhou, B., Preparation and evaluation of itraconazole dihydrochloride for the solubility and dissolution rate enhancement. International Journal of Pharmaceutics 367:1–2 (2009), 109–114.
24. Thomsen, R., Christensen, M.H., MolDock: A new technique for high-accuracy molecular docking. Journal of Medicinal Chemistry 49:11 (2006), 3315–3321.
25. Veiga, F., Teixeira-Dias, J.J.C., Kedzierewicz, F., Sousa, A., Maincent, P., Inclusion complexation of tolbutamide with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. International Journal of Pharmaceutics 129:1 (1996), 63–71.
26. Woranuch, S., Yoksan, R., Eugenol-loaded chitosan nanoparticles: I. Thermal stability improvement of eugenol through encapsulation. Carbohydrate Polymers 96:2 (2013), 578–585.
27. Wu, H., Liang, H., Yuan, Q., Wang, T., Yan, X., Preparation and stability investigation of the inclusion complex of sulforaphane with hydroxypropyl-β-cyclodextrin. Carbohydrate Polymers 82:3 (2010), 613–617.
28. Yuan, C., Jin, Z., Xu, X., Inclusion complex of astaxanthin with hydroxypropyl-beta-cyclodextrin: UV, FTIR, 1H NMR and molecular modeling studies. Carbohydrate Polymers 89:2 (2012), 492–496.
29. Zhang, Y., Lipton, P., Cytosolic Ca2+ changes during in vitro ischemia in rat hippocampal slices: Major roles for glutamate and Na+-dependent Ca2+ release from mitochondria. Journal of Neuroscience 19:9 (1999), 3307–3315.